EYPT (EyePoint) FFO


EYPT EyePoint Inc EYPT
34 GF Score
Price $13.66
GF Value $0.83
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is EyePoint FFO?

FFO (Funds from operations) only applies to REITs.

EYPT
34GF Score
EyePoint Inc EYPT
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is EyePoint (EYPT) Overvalued in 2026?

Based on GuruFocus' analysis, EyePoint stock appears to be overvalued. The current stock price of $13.66 is trading 1545.8% above its estimated GF Value™ of $0.83. GuruFocus considers EyePoint to be Significantly Overvalued.

Key valuation signals for EYPT:

  • FFO:
  • GF Value™: $0.83 vs. price of $13.66 (1545.8% above fair value)
  • GF Score™: 34/100 with 7 warning signs

No single metric tells the full story. See the EYPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

EyePoint Business Description

Other Exchanges PV3B:Germany
Address 480 Pleasant Street, Suite C-400, Watertown, MA, USA, 02472
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
34GF Score

Get the complete analysis for EYPT

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.66
Price
$0.83
GF Value